Diversity in clinical trials has been a long-standing issue across clinical research. Studies have historically failed to represent the patient population, with the majority of patients enrolled in trials being White, younger men. This has caused not only gaps in the industry’s understanding of how treatments in certain disease areas broadly affect diverse populations, but also inequitable access to treatments. As a result, lack of representation can also impede healthcare decision-making and future clinical development.
Download to find out more.